Sandoz to appeal against Amgen biosimilar ruling

13-08-2019

Sarah Morgan

Sandoz to appeal against Amgen biosimilar ruling

Sandoz has confirmed that it plans to appeal against a decision that upheld the validity of two of Amgen’s patents for its arthritis treatment Enbrel (etanercept), effectively blocking the launch of Sandoz’s biosimilar version.


Sandoz, Amgen, Enbrel, biosimilars, patent validity, FDA, Erelzi, arthritis, Roche

LSIPR